Literature DB >> 8930655

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.

F Arienti1, J Sulé-Suso, F Belli, L Mascheroni, L Rivoltini, C Melani, M Maio, N Cascinelli, M P Colombo, G Parmiani.   

Abstract

We have immunized advanced melanoma patients with a HLA-A2-compatible human melanoma line genetically modified to release interleukin-2 (IL-2), to elicit or increase a T cell-mediated anti-melanoma response that may affect distant lesions. Twelve stage-IV patients were injected subcutaneously at days 1, 13, 26, and 55 with IL-2 gene-transduced and irradiated melanoma cells at doses of 5 or 15 x 10(7) cells. Both local and systemic toxicities were mild, consisting of transient erythema at the vaccination site; fever occurred in a minority of patients. Three mixed responses were recorded. Seven patients were evaluable for immunological studies. Mixed tumor-lymphocyte cultures carried out with different allogeneic HLA-A2-matched melanoma lines as stimulators and targets revealed an increase in the MHC-unrestricted, but no changes in the MHC-restricted, cytotoxicity in peripheral blood lymphocytes (PBL) obtained after vaccination as compared with those obtained before vaccination. Increased recognition of the tyrosinase 368-376 peptide occurred in post-vaccination PBL of one patient, whereas a weak increase in recognition of the gp100 280-288 peptide was detectable in another patient; these 2 patients also recognized the gp100 457-466 peptide. After in vitro, stimulation with the only available autologous melanoma line, CD4+ cells with autologous tumor-specific cytotoxicity and ability to release interferon-gamma (IFN-gamma) were found in post- but not in pre-vaccination PBL. In the same patient, as well as in another patient, limiting dilution analysis showed that vaccination resulted in an increased frequency of melanoma-specific cytotoxic T lymphocyte (CTL) precursors. These results indicate that vaccination with cells releasing IL-2 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although this response occurred in a minority of the melanoma patients studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930655     DOI: 10.1089/hum.1996.7.16-1955

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

Review 1.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

3.  Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.

Authors:  Ryuichi Saito; Yu Sawada; Motonobu Nakamura
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

4.  Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.

Authors:  T Schweighoffer
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 2.874

5.  Mechanisms of local immunosuppression in cutaneous melanoma.

Authors:  M E Polak; N J Borthwick; F G Gabriel; P Johnson; B Higgins; J Hurren; D McCormick; M J Jager; I A Cree
Journal:  Br J Cancer       Date:  2007-06-12       Impact factor: 7.640

Review 6.  Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Authors:  Markus Moehler; Katrin Goepfert; Bernd Heinrich; Caroline J Breitbach; Maike Delic; Peter Robert Galle; Jean Rommelaere
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.